Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adimab has announced the initiation of the first human clinical trial of MM-151, an oligoclonal therapeutic, by Merrimack Pharmaceuticals.
Subscribe to our email newsletter
The oligoclonal therapeutic consists of a mixture of three fully human monoclonal antibodies which are designed to bind to non-overlapping epitopes of the epidermal growth factor receptor (EGFR).
Adimab’s three lead antibodies and a number of backups were licensed exclusively to Merrimack.
Adimab CEO Tillman Gerngross said they launched their platform two and a half years ago and are now seeing the first programs enter the clinic.
"Merrimack had a validated target and an understanding of the biology necessary for a novel antibody therapeutic," Gerngross added.